Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a newer class of glucose-lowering drugs, have emerged as promising candidates for mitigating diabetes-associated cognitive decline (12, 13). Here, SLC5A2 is linked to diabetes mellitus.